Nevirapine (Viramune®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000539
English
Authors' recommendations:
Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets.
Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used.
Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=194846&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Nevirapine
- Reverse Transcriptase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.